Navigation Links
Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
Date:3/17/2010

class="xn-money">$566,000 as compared to $435,000 in the comparable quarter of fiscal 2009, an increase of 30%.  This increase is primarily due to licensing fees and costs of $130,000 incurred in connection with licensing our third oncology drug candidate Bithionol.  

General and administrative expenses for the third quarter of 2010 were $596,000 as compared to $463,000 in the comparable quarter of 2009, an increase of 29%.  This increase is primarily due to the development of our corporate infrastructure to support our effort to grow our Preclinical eValuation services and includes increased salaries and  bonuses, legal, accounting, marketing, and office rent expenses.

For the third quarter ended January 31, 2010, the Company reported a net loss of $784,000 or $0.02 per share compared to a net loss of $563,000 or $0.02 per share for the corresponding quarter in 2009.

The Company's cash position on January 31, 2010 was $1,479,000 compared to $1,728,000 at '/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
2. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
3. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
4. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
5. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
6. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
7. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
8. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
9. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
10. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
11. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Warren, NJ (PRWEB) May 22, 2015 ... a new white paper that explores the potential of ... industries. The white paper was developed to help life ... they can leverage data to gain critical business insights. ... generated large amounts of data driven by patient profiling, ...
(Date:5/21/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... proprietary technologies and products for advanced microarray diagnostics, today ... fiscal quarter ended March 31, 2015. ... with our existing customers and to develop new opportunities," ... SQI. "The delivery of a fully automated sqidlite™ system ...
(Date:5/21/2015)... 2015 Specialty Pharmacy Times has ... admitted to BPA Worldwide as a business publication ... audience data for Specialty Pharmacy Times based on ... becoming a member of BPA Worldwide, Specialty Pharmacy ... clients with the most reliable, unequaled data,” said ...
(Date:5/21/2015)... 2015  Prima Biomed Ltd. (NASDAQ: PBMD ) ... become a leader in the development of immunotherapeutic products ... final CVac data from the Phase II CAN-003 ovarian ... a clinically meaningful improvement in Overall Survival ("OS") over ... In the group of second remission patients (n=20), ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Specialty Pharmacy Times Joins BPA Worldwide 2Correction Continues after Big Move - BrokerBank Securities, Inc. 2
... SAN MARINO, Calif., Oct. 29 Epeius Biotechnologies,Corporation ... Rexin-G for pancreatic cancer and breast cancer in ... genetic medicine that,is designed to seek out and ... spread throughout the body. Clinical data from on-going,studies ...
... Inc.,(Nasdaq: NVAX ) a clinical-stage vaccine company, announced ... will be presenting at,the Oppenheimer 19th Annual Healthcare Conference ... Waldorf-Astoria Hotel, New York city. Dr. Singhvi,will provide an ... link to the live presentation can be accessed via,the ...
... Oct. 29 Genomas(R) today announced,that Gualberto Ruano, ... the Life,Sciences & Healthcare Venture Summit in New ... ET. Dr. Ruano,s presentation, Bringing DNA-Guided Medicine to,the ... update on the,Company,s programs in cardiovascular medicine (statins) ...
Cached Biology Technology:Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan 2
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/21/2015)... BURNABY, Canada , April 21, 2015 ... spending and evolving government policies are boosting access control ...   According to a recently published report ... & Opportunities, 2020 ", the access control systems market ... to nearly USD1.2 billion by 2020.The access control systems ...
(Date:4/14/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® smart ... Design Awards under the category  ,Product Design – Technology,. ... are part of a global multi-disciplinary awards program. The ... marketplace, industry and judging panel. Winners will be announced ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... previously thought to be disordered may in fact have an ... -- according to a study published by researchers at Fox ... Structure (Cell Press). The researchers published ... serves as a means of bringing together molecular signals between ...
... risen sharply in developed countries in the wake of the ... the condition. Foot problems are the most common cause of ... serious complications such as nerve damage and problems with the ... slow-healing wounds and foot ulcers which, if they get infected ...
... the principle of supply and demand at least at the ... proteins, are required at all times. That means most of their ... case in higher organisms. In the simplest case, a transcription factor ... that are regulated in a somewhat more complex manner, on the ...
Cached Biology News:'Disordered' amino acids may really be there to provide wiggle room for signaling protein 2'Disordered' amino acids may really be there to provide wiggle room for signaling protein 3Protective footwear for diabetics at a high-street price 2Protective footwear for diabetics at a high-street price 3The evolution of gene regulation 2The evolution of gene regulation 3
... family of calcium binding proteins such as calmodulin ... an alpha and beta chain whereas S100B is ... is also expressed in the antigen presenting cells ... interdigitating reticulum cells in the paracortex of lymph ...
LEAF™ Purified anti-human/mouse/rat ICOS...
Peptide-affinity Purified Polyclonal Antibody to MTR...
Purified anti-eIF-4E...
Biology Products: